
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
Experts in breast oncology review 4 clinical cases and discuss individualized treatment approaches for each patient.






